Animal Health

Japan is the second largest market in the world for animal health products, with annual sales of approximately 83 billion yen. Due to the high cost of development of animal drugs, most new products are now developed on a worldwide basis by a few global companies. Many new innovative products come from Europe. Even though each product can only be registered after going through a rigorous review process in Europe and the USA, additional testing is required in Japan before approval is granted to bring it to market. In some cases, a product that is readily available to veterinarians and animal owners in Europe cannot be registered in Japan due to the unique local regulatory requirements. The committee is working to achieve increased harmonisation of regulatory requirements, which would improve access in Japan to innovative animal health products.

View Issues and Recommendations – (English | Japanese) - Updated

Chairman:
Dr. Tadashi Nagata
Director, Merial Japan Ltd.
Sanno Grand Bldg. 8F.
2-14-2 Nagatacho
Chiyoda-ku,Tokyo 100-0014
Tel: +81-3-5251-8183 | Fax: +81-3-5251-8195

Members:
Bayer Yakuhin, Ltd./Animal Health Division
Boehringer Ingelheim Vetmedica Japan Co., Ltd.
Merial Japan Ltd.
Novartis Animal Health K.K.
Virbac Japan Co. Ltd.